{"generic":"Eluxadoline","drugs":["Eluxadoline","Viberzi"],"mono":{"0":{"id":"jyp9s0","title":"Generic Names","mono":"Eluxadoline"},"1":{"id":"jyp9s1","title":"Dosing and Indications","sub":[{"id":"jyp9s1b4","title":"Adult Dosing","mono":"<ul><li><b>Irritable bowel syndrome with diarrhea:<\/b> 100 mg ORALLY 2 times daily; discontinue therapy in patients who have severe constipation for more than 4 days<\/li><li><b>Irritable bowel syndrome with diarrhea:<\/b> 75 mg ORALLY 2 times daily in patients who do not have a gallbladder; discontinue therapy in patients who have severe constipation for more than 4 days<\/li><\/ul>"},{"id":"jyp9s1b5","title":"Pediatric Dosing","mono":"Safety and efficacy not established "},{"id":"jyp9s1b6","title":"Dose Adjustments","mono":"<ul><li><b>Hepatic impairment, mild (Child-Pugh class A) or moderate (Child-Pugh class B):<\/b> Reduce to 75 mg orally 2 times daily<\/li><li><b>Hepatic impairment, severe (Child-Pugh class C):<\/b> Contraindicated<\/li><li><b>Concomitant use with OATP1B1 inhibitors:<\/b> Reduce to 75 mg orally 2 times daily<\/li><li><b>Cannot tolerate 100 mg dose:<\/b> Reduce to 75 mg orally 2 times daily<\/li><\/ul>"},{"id":"jyp9s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Irritable bowel syndrome with diarrhea<br\/>"}]},"3":{"id":"jyp9s3","title":"Contraindications\/Warnings","sub":[{"id":"jyp9s3b9","title":"Contraindications","mono":"<ul><li>Alcoholism, alcohol abuse, alcohol addiction, or consumption of more than 3 alcoholic drinks daily<\/li><li>Biliary duct obstruction, known or suspected<\/li><li>Chronic or severe constipation, history of or sequelae from constipation<\/li><li>Hepatic impairment, severe<\/li><li>Mechanical gastrointestinal obstruction, known or suspected<\/li><li>Pancreatitis, history of<\/li><li>Sphincter of Oddi disease or dysfunction<\/li><li>Structural disease of pancreas (ie, known or suspected pancreatic duct obstruction)<\/li><\/ul>"},{"id":"jyp9s3b10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- Pancreatitis, not associated with sphincter of Oddi spasm, may occur; monitoring recommended; discontinue use if symptoms suggestive of pancreatitis occur; may resolve upon discontinuation<\/li><li>Hepatic:<\/li><li>-- Increased risk of sphincter of Oddi spasm possibly resulting in pancreatitis or hepatic enzyme elevations; discontinue use if symptoms occur and do not restart if biliary duct obstruction or sphincter of Oddi spasm have developed during use<\/li><li>-- Absence of gallbladder increases risk for sphincter of Oddi spasm; consider alternative therapies or if used, monitor for symptoms<\/li><li>-- Hepatic impairment; dose adjustment and monitoring recommended<\/li><li>Concomitant use:<\/li><li>-- Avoid chronic or excessive alcohol use<\/li><li>-- Avoid use with drugs (eg, alosetron, anticholinergics, opioids) that may lead to constipation; loperamide may be used occasionally for acute diarrhea<\/li><\/ul>"},{"id":"jyp9s3b11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"jyp9s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jyp9s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Dermatitis, Rash, Urticaria<\/li><li><b>Gastrointestinal:<\/b>Flatulence (3%), Nausea (7% to 8%), Swollen abdomen (3%), Viral gastroenteritis (1% to 3%), Vomiting (4%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised (2% to 3%), AST\/SGOT level raised (2% or less)<\/li><li><b>Neurologic:<\/b>Dizziness (3%), Sedated (2% or less), Somnolence (2% or less)<\/li><li><b>Psychiatric:<\/b>Euphoria (2% or less)<\/li><li><b>Respiratory:<\/b>Asthma (2% or less), Bronchitis (3%), Bronchospasm (2% or less), Nasopharyngitis (3% to 4%), Upper respiratory infection (3% to 5%)<\/li><li><b>Other:<\/b>Feeling intoxicated (2% or less), Nasopharyngitis (2% to 3%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (6% to 7%), Constipation (7% to 8%), Pancreatitis (0.2% to 0.3%), Spasm of sphincter of Oddi (0.2% to 0.8%)<\/li><li><b>Respiratory:<\/b>Respiratory failure (2% or less)<\/li><\/ul>"},"6":{"id":"jyp9s6","title":"Drug Name Info","sub":{"0":{"id":"jyp9s6b17","title":"US Trade Names","mono":"Viberzi<br\/>"},"2":{"id":"jyp9s6b19","title":"Class","mono":"<ul><li>Antidiarrheal<\/li><li>Opioid Agonist\/Antagonist<\/li><\/ul>"},"3":{"id":"jyp9s6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"jyp9s7","title":"Mechanism Of Action","mono":"Eluxadoline has agonist activity at the mu- and kappa-opioid receptors and antagonist activity at the delta-opioid receptor. Interaction with opioid receptors occurs in the gut.<br\/>"},"8":{"id":"jyp9s8","title":"Pharmacokinetics","sub":[{"id":"jyp9s8b23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 1.5 hours (fed); 2 hours (fasting)<\/li><li>Effects of food: Cmax decreased 50%, AUC decreased 60% with high-fat meal<\/li><\/ul>"},{"id":"jyp9s8b24","title":"Distribution","mono":"Protein binding: 81% <br\/>"},{"id":"jyp9s8b25","title":"Metabolism","mono":"<ul><li>Site of metabolism: unknown<\/li><li>Substrate of OATP1B1<\/li><li>Inhibitor of OATP1B1 and BCRP<\/li><\/ul>"},{"id":"jyp9s8b26","title":"Excretion","mono":"<ul><li>Fecal: 82.2%<\/li><li>Renal: Less than 1%<\/li><\/ul>"},{"id":"jyp9s8b27","title":"Elimination Half Life","mono":"3.7 to 6 hours <br\/>"}]},"9":{"id":"jyp9s9","title":"Administration","mono":"<b>Oral<\/b><br\/>Take with food <br\/>"},"10":{"id":"jyp9s10","title":"Monitoring","mono":"<ul><li>Signs of sphincter of Oddi spasm, in patients without a gallbladder (eg, elevated liver enzymes); especially during the first few weeks of treatment<\/li><li>Symptoms of sphincter of Oddi spasm, in patients without a gallbladder (eg, abdominal pain or pancreatitis); especially during the first few weeks of treatment<\/li><li>New or worsening abdominal pain that may spread to the back or shoulder and may occur with or without nausea and vomiting<\/li><li>Impaired mental or physical abilities necessary to perform potentially hazardous activities (eg, driving, operating machinery), in patients with hepatic impairment<\/li><\/ul>"},"13":{"id":"jyp9s13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report symptoms of sphincter of Oddi spasm or pancreatitis.<\/li><li>Instruct patient to report severe constipation.<\/li><li>Side effects may include nausea, abdominal pain or distension, vomiting, upper respiratory tract infection, nasopharyngitis, bronchitis, dizziness, or rash.<\/li><li>Encourage patient to take drug with food.<\/li><li>Tell patient to avoid chronic or acute excessive alcohol use due to increased risk of pancreatitis.<\/li><li>Advise patient to skip a missed dose and continue with the regular dosing schedule.<\/li><\/ul>"}}}